21 Invest announces Rocamed’s first transformative build-up with the acquisition of Delmont Imaging, a renowned specialist in gynecological medical devices.

Rocamed is a fast-growing European MedTech platform specialized in minimally invasive endo-urology. Founded in 2012, the Group has developed into a reference player in the treatment of kidney stones, supported by a comprehensive range of devices, consumables and accessories, and a commercial footprint spanning more than 50 countries. Since joining 21 Invest’s portfolio in October 2024, Rocamed has accelerated its strategic development through organizational strengthening, sustained product innovation and continued international expansion.

Founded in 2016, Delmont Imaging is a highly complementary business that has rapidly established itself as a reference in diagnostic and operative hysteroscopy. The company designs and manufactures a full range of high-end devices and imaging systems and today serves more than 50 countries through an established network of distributors. Strong clinical credibility, double-digit organic growth and continued investment in innovation have enabled Delmont Imaging to build a solid position in a resilient and steadily expanding market.

This acquisition marks a major milestone in Rocamed’s strategy to build a unique uro-gyn platform of medical devices. Combining Rocamed’s expertise in urology with Delmont Imaging’s leadership in hysteroscopy significantly broadens the Group’s clinical offering and creates meaningful opportunities for commercial and operational synergies. Following the transaction, the Group will generate consolidated sales in excess of €40 million, providing additional scale to accelerate international development and bring new minimally invasive solutions to patients worldwide.

Antoine Vigneron, Partner, and Baptiste Gaud, Investment Manager at 21 Invest, comment: “This build-up marks an important step in Rocamed’s development and reinforces its ambition to become a leading uro-gyn MedTech platform. The complementarity between Rocamed and Delmont Imaging opens up new growth opportunities across both urology and gynecology, while accelerating our innovation capabilities to better serve practitioners and patients.”

Olivier Jaigu, CEO of Rocamed, adds: “The integration of Delmont Imaging represents a natural extension of Rocamed’s mission to deliver high-quality minimally invasive technologies to healthcare professionals. Our combined capabilities will allow us to support clinicians across a wider therapeutic spectrum, while accelerating our innovation agenda.”